Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #38 on Assembly Biosciences Inc (ASMB)
DewDiligence
03/10/22 4:54 PM
#39 RE: DewDiligence #38
06/06/22 11:32 AM
#43 RE: DewDiligence #38
06/21/22 2:03 PM
#44 RE: DewDiligence #38
Assembly Biosciences…plans to host a webcast on Tuesday, July 26, 2022 from 1:30-2:30 pm PT/4:30-5:30 pm ET to introduce its new research program advancing a novel, small molecule interferon-alpha receptor (IFNAR) agonist designed to selectively activate the interferon-alpha pathway within the liver and offer the convenience of oral dosing.
07/20/22 5:00 PM
#45 RE: DewDiligence #38
Assembly Biosciences will discontinue clinical development of its first-generation investigational core inhibitor, VBR, based on review of interim on-treatment efficacy from the two ongoing VBR triple combination studies. The data indicate that the triple combinations do not show a benefit in multiple key viral parameters compared to the dual combinations without VBR in either study. …As a result of these data, Study 203, an open-label, Phase 2 study evaluating the triple combination of VBR + nucleos(t)ide analogue reverse transcriptase inhibitors (NrtI) + interferon (PEG-IFN-alpha) versus the dual combinations of VBR + NrtI and NrtI + PEG-IFN-alpha, will conclude immediately. No additional clinical studies of VBR are currently planned.
[ASMB’s] first HBV core inhibitor, VBR (f/k/a ABI-H0731), failed in a 2-drug combination with a nucleoside (#msg-159327881) and is now in various combination trials with external agents (#msg-157913492, #msg-166413748). These trials have a low chance of success (IMO) because VBR is a weak agent on its own, so there would need to be an astonishing degree of synergy for such combinations to provide a functional cure for HBV (the goal that all HBV companies are pursuing). All told, the VBR program looks like an example of Zebra’s Law.
03/22/23 5:17 PM
#50 RE: DewDiligence #38